Wall Street Zen Upgrades Evolus (NASDAQ:EOLS) to Buy

Evolus (NASDAQ:EOLS) was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday.

EOLS has been the topic of several other reports. BTIG Research reissued a “buy” rating and set a $13.00 price objective on shares of Evolus in a research report on Wednesday, June 17th. Weiss Ratings raised shares of Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 15th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Evolus currently has a consensus rating of “Moderate Buy” and a consensus target price of $14.50.

Evolus Stock Performance

Evolus stock opened at $7.59 on Friday. Evolus has a 12 month low of $3.86 and a 12 month high of $7.95. The company has a market capitalization of $501.32 million, a price-to-earnings ratio of -14.60 and a beta of 1.35. The business’s fifty day simple moving average is $6.50 and its two-hundred day simple moving average is $5.54.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of EOLS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Evolus by 5.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 33,289 shares of the company’s stock worth $400,000 after buying an additional 1,838 shares during the last quarter. Millennium Management LLC boosted its holdings in shares of Evolus by 1.7% during the 1st quarter. Millennium Management LLC now owns 1,392,028 shares of the company’s stock valued at $16,746,000 after acquiring an additional 23,605 shares during the last quarter. Jones Financial Companies Lllp purchased a new stake in shares of Evolus during the 1st quarter valued at about $158,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Evolus by 36.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,565 shares of the company’s stock valued at $1,883,000 after acquiring an additional 41,513 shares during the last quarter. Finally, Jane Street Group LLC grew its stake in shares of Evolus by 484.8% in the first quarter. Jane Street Group LLC now owns 69,947 shares of the company’s stock worth $841,000 after acquiring an additional 57,987 shares during the period. 90.69% of the stock is owned by institutional investors.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.